BLFS BioLife Solutions Inc.

XNAS 38.61 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

BLFS $38.61 —
Key stats
$38.61
52-Week Range
$17.86 – $39.76
YTD
+61.62%
IV Rank (30D)
37.73
Straddle Price
$5.62
P/C Vol Ratio (Nov 20 expiry)
0.25
Market Cap
$1.9B
Open
$37.16
Day Range
$36.95 – $38.83
Volume
4,445,978
Prev Close
$37.30
Fair Value
MODEL: NEUTRAL

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.24%
Beta vs SPY1.68
Cost of Equity (CAPM)14.09% (VRP-adj)
WACC14.29%
Volatility Risk Premium+8.7pp (IV − HV30), ERP adj +28bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+1.4%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.01 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$0.0B
Return on Equity (TTM)13.8%
Book / Price22.2%
Gross Margin (TTM)63.9%
FCF Margin (TTM)7.0%
Debt / Equity0.00
Quality Score2/6 — normal (10y DCF)
SMA 50$35.70 (Market Anchor value)
SMA 20 / Bollinger Mid$37.08
Bollinger Width / SMA2041.8% (drives anchor stability)
Net Debt$-0.0B
Market Cap$2B
Peers used for multiples: GKOS, ITGR, LNTH, OGN, PSNL, PTGX, SUPN, TECH
60-Day Conviction
19%
20-Day Fair Value
≈ by Nov 4, 2026
$39.00
α +1.0% rank 41%
conviction
63%
40-Day Fair Value
≈ by Dec 3, 2026
$39.27
α +1.7% rank 37%
conviction
51%
60-Day Fair Value
≈ by Jan 1, 2027
$38.81
α +0.5% rank 34%
conviction
19%
MethodImplied PriceWeightDetail
DCF $1.70 26%
DDM (Gordon) n/a 0%
Peer P/E $39.73 8% median 33.5× · 5 peers
Peer EV/EBITDA $3.74 8% median 24.5× · 6 peers
Peer P/B $44.46 8% median 5.2× · 8 peers
Peer P/S $14.40 8% median 6.8× · 8 peers
Market Anchor (SMA50) $35.70 43% stability 82% (BB-width)
Options Expected (B-L 30d) $37.46 0% 6 strikes · skew +0.74
As of 2026-10-06 · updated
About
Industry (SIC)
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS (3845) · industry map
Exchange
XNAS
Market Cap
$1.9B
Employees
155
List Date
1989-11-22
CIK
0000834365
Last Earnings
Aug 6 after close · +2.2% vs ±7.1% expected
Headquarters
Bothell, WA
Homepage
https://www.biolifesolutions.com

BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart

Markers: Click a marker type to show or hide it. Earnings turn amber when the stock moved more than options implied; hollow markers are still to come, or insider trades under a 10b5-1 plan. Intraday times are New York time; shaded bars are pre-market and after-hours.

Seasonality
Month'21'22'23'24'25'26Avg
Jan-10.21%-19.98%32.65%6.38%4.30%-8.75%0.73%
Feb-0.91%-22.65%-1.11%-5.95%-9.84%8.37%-5.35%
Mar-11.50%-4.13%-4.61%3.23%-6.81%-15.28%-6.52%
Apr-4.88%-46.36%-12.77%-2.01%5.61%9.28%-8.52%
May-5.02%4.10%29.01%22.88%-11.06%17.49%9.57%
Jun37.93%3.37%-4.33%0.80%4.11%6.05%7.99%
Jul5.02%31.63%-7.53%15.54%-1.85%9.87%8.78%
Aug19.93%22.40%-31.70%10.79%20.40%15.30%9.52%
Sep-30.05%-4.09%3.06%2.50%0.67%9.53%-3.06%
Oct24.82%6.09%-24.80%-3.07%6.66%4.98%2.45%
Nov-29.41%-11.83%20.92%14.13%-4.92%--*-2.22%
Dec-0.61%-16.78%22.64%-4.80%-4.84%---0.88%
Total-24.30%-58.80%-2.21%73.22%-1.62%66.16%8.74%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $37.08
SMA 50: $35.70
SMA 200: $26.62
Current: $38.61
EMA 12: $37.83
EMA 26: $36.99
MACD: 0.8351 | Signal: -0.0597
BULLISH
ADX (14): 37.36
TREND
+DI: 26.22
−DI: 16.16

Momentum Oscillators

RSI (14): 60.55
NEUTRAL
Stoch %K: 51.34
Stoch %D: 59.37
Williams %R: -29.95

Volume & Volatility

BB Upper: $39.95
BB Lower: $34.21
NEUTRAL
OBV: 19,911,411
Vol SMA 20: 1,224,272
Vol ROC: 993.45%
ATR: $1.14
True Range: $1.88
HV 20: 31.0%
HV 30: 30.6%
HV 60: 34.9%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-07T00:00:00 – 2026-10-05T00:00:00
AI Analysis

BLFS (BioLife Solutions) - Comprehensive Stock Analysis Report


Executive Summary

Overall Assessment: BULLISH with 7.5/10 Confidence

Key Drivers: Strong technical momentum with bullish MACD crossover, elevated volume (+177% ROC), price above all major moving averages, and positive options sentiment. Primary risks include pending shareholder lawsuit investigation, IV premium inflation (47.5% above realized volatility), and upcoming Q1 2026 earnings on May 7.

Investment Thesis: BLFS exhibits constructive technical setup with price trading 1.4% above SMA20 and 40% above its 200-day moving average, supported by robust ADX reading (38.41) confirming strong uptrend. However, the sharp IV premium and litigation investigation create asymmetric downside risks that warrant cautious position sizing ahead of earnings catalyst on May 7.

Recent News Sentiment Impact: Mixed signals with 2 positive catalysts (INTERPHEX award, Qkine supply agreement) offset by litigation concern. News headwinds appear limited given positive operational developments, but the Halper Sadeh investigation announcement (July 30) suggests potential near-term volatility risk.


Technical Analysis

Trend Direction

| Timeframe | Assessment | Confidence | |-----------|-----------|-----------| | Short-term (1-4 weeks) | BULLISH | HIGH | | Medium-term (1-3 months) | BULLISH | HIGH | | Long-term (3-12 months) | BULLISH | MEDIUM |

Detailed Trend Analysis:

  • Price at $37.30 trades above all major moving averages (SMA20: $36.91, SMA50: $35.52, SMA200: $26.55)
  • Distance from SMA200 indicates +40.5% separation — strong uptrend confirmation
  • EMA12 ($37.68) > EMA26 ($36.86) — bullish short-term momentum
  • ADX (14) at 38.41 confirms strong trending regime (readings >35 indicate powerful directional movement)
  • +DI (23.67) >> -DI (18.32) — upside pressure dominating downside pressure

Support/Resistance Levels

| Level | Price | Rationale | Significance | |-------|-------|-----------|--------------| | Immediate Support | $36.91 | SMA20 (short-term floor) | CRITICAL - Recent base | | Secondary Support | $35.52 | SMA50 (medium-term support) | STRONG - Trend confirmation | | Major Support | $34.03 | Bollinger Band Lower | TECHNICAL - Mean reversion point | | Resistance 1 | $39.80 | Bollinger Band Upper | MODERATE - Profit-taking zone | | Resistance 2 | $41.00+ | Untested (historical) | SPECULATIVE |

Key Observation: Support levels are densely clustered ($34.03-$36.91), providing multiple cushions. Resistance at Bollinger Upper Band ($39.80) represents +6.7% upside to current levels.

Momentum Signals

RSI (14): 53.46 — NEUTRAL

  • Reading in neutral zone (30-70) with slight bullish bias
  • Not overbought, allowing room for further appreciation
  • Suggests momentum has legs without extremes warning of reversal

MACD: 0.82 / Signal: -0.09 / Histogram: 0.91 — BULLISH CROSSOVER

  • Positive Histogram (0.91) indicates MACD line above signal line
  • Early-stage bullish crossover with histogram expanding — momentum building
  • Suggests renewed buying pressure and uptrend acceleration potential

Stochastic Oscillators (Mixed):

  • %K: 55.41 — neutral midzone
  • %D: 71.24 — elevated but not overbought (threshold 80)
  • Slight divergence suggests momentum may be plateauing near-term
  • Williams %R at -57.88 confirms neutral positioning without extremes

Bollinger Bands: NEUTRAL

  • Price at $37.30 positioned in middle third of bands (neither overbought nor oversold)
  • Band width at 15.64 shows moderate volatility environment
  • No squeeze setup currently, but room exists for expansion

Volume Analysis

Critical Volume Signals:

  • Volume ROC: +177.05% — Exceptional volume surge indicating institutional or retail capitulation buying
  • Volume SMA20: 1,019,188 shares — current volume significantly elevated vs baseline
  • OBV: 14,962,208 — positive cumulative flow supporting price appreciation
  • Interpretation: Volume validation of price advance suggests conviction in uptrend; not a weak rally

Institutional Positioning Implication: High volume ROC combined with positive OBV suggests institutional accumulation phase rather than retail speculation. This reinforces bullish bias.


News & Sentiment Analysis

Recent Headlines Summary (Last 10 Articles)

| Date | Headline | Sentiment | Relevance | |------|----------|-----------|-----------| | 2026-07-30 | Shareholder Investigation (Halper Sadeh) | NEGATIVE | ACUTE RISK | | 2026-04-23 | Q1 2026 Earnings Announcement | NEUTRAL | Catalyst: May 7 | | 2026-04-21 | INTERPHEX 2026 Biotech Innovation Award | POSITIVE | Product validation | | 2026-02-26 | Q4 2025 & FY2025 Results Report | POSITIVE | Earnings beat signal | | 2026-02-17 | Q4/FY2025 Earnings Announcement Notice | NEUTRAL | Procedural | | 2026-02-12 | Qkine Supply Agreement (Multi-Year) | POSITIVE | Revenue expansion |

Sentiment Aggregate: 3 Positive / 2 Neutral / 1 Negative = 50% Positive Skew

Sentiment Assessment

Overall Narrative: POSITIVE with HEDGING RISK

Bullish Evidence:

  • Product awards (INTERPHEX recognition for CellSeal® CryoCase) validate innovation pipeline
  • Multi-year supply agreements (Qkine) signal revenue diversification and market expansion
  • Positive earnings results language in Feb 26 announcement suggests operational health

Bearish Headwind:

  • Halper Sadeh shareholder investigation (July 30) alleges unfair shareholder value realization
  • Investigation timing during strong uptrend suggests activist pressure for deal or governance changes

Catalyst Identification

Immediate (1-7 days):

  • Shareholder investigation developments/press releases
  • Daily news flow on litigation status

Near-term (1-4 weeks):

  • Q1 2026 Earnings Report: May 7, 2026 — CRITICAL (earnings timing overlaps with current data)
  • Potential analyst reactions and guidance updates
  • Investigation updates from Halper Sadeh

Medium-term (1-3 months):

  • Product launch/commercialization updates for CellSeal® or cytokine products
  • Strategic partnership announcements (following Qkine model)
  • Potential M&A activity if shareholder pressure escalates

Market Narrative Alignment

Technical vs. News Conflict Analysis:

| Signal | Technical | News | Alignment | |--------|-----------|------|-----------| | Trend Direction | STRONG BULLISH | Mixed (positive ops + litigation) | PARTIAL | | Momentum | BUILDING (MACD crossover) | Positive product/revenue news | ALIGNED | | Risk Appetite | Elevated volume | Shareholder investigation | CONFLICTED |

Interpretation: The divergence between strong technical momentum and litigation concerns creates asymmetric risk structure. Technical analysis is forward-looking to earnings; news investigation may not be fully priced into technicals yet.


Risk & Volatility Assessment

Beta Interpretation

Beta: 1.10 (vs SPY)

  • Classification: ABOVE-MARKET VOLATILITY
  • 10% amplification of market moves — moves faster up AND down than broad market
  • Alpha: +0.30 suggests stock has outperformed market expectations (positive manager/business performance)
  • Correlation: 0.33 indicates weak correlation to market — stock-specific drivers dominate

Risk Implication: BLFS is a non-correlated,

Generated
Earnings History
18 of 23 under expected move
Avg Expected Move
14.69%
Avg Actual Move
7.76%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-03-22 After-Close 15.84% 8.84% 0.56x Within
2021-05-13 After-Close 12.87% 0.71% 0.06x Within
2021-08-12 After-Close 4.64% 5.70% 1.23x Exceeded
2021-11-12 After-Close 8.68% 5.55% 0.64x Within
2022-01-10 After-Close 8.07% 1.53% 0.19x Within
2022-02-28 After-Close 13.62% 0.89% 0.07x Within
2022-08-09 After-Close 15.58% 18.77% 1.20x Exceeded
2022-11-09 After-Close 21.97% 42.77% 1.95x Exceeded
2023-03-16 After-Close 10.01% 7.71% 0.77x Within
2023-05-10 After-Close 13.33% 1.93% 0.14x Within
2023-08-08 After-Close 10.11% 28.71% 2.84x Exceeded
2023-10-23 After-Close 25.41% 1.02% 0.04x Within
2024-01-08 After-Close 9.63% 0.06% 0.01x Within
2024-05-09 After-Close 18.43% 8.50% 0.46x Within
2024-08-08 Pre-Market 13.72% 3.13% 0.23x Within
2024-11-12 After-Close 8.77% 9.02% 1.03x Exceeded
2025-05-08 Pre-Market 21.44% 4.78% 0.22x Within
2025-08-07 After-Close 18.65% 9.88% 0.53x Within
2025-11-06 After-Close 20.91% 4.03% 0.19x Within
2026-01-12 After-Close 19.97% 0.58% 0.03x Within
2026-02-26 After-Close 22.02% 7.65% 0.35x Within
2026-05-07 After-Close 17.08% 4.67% 0.27x Within
2026-08-06 After-Close 7.07% 2.15% 0.30x Within

Earnings calendar: this week’s reports with expected vs actual moves →

BLFS Options Activity & IV Rank

BLFS IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 46.4%
7-DTE IV: 41.9%
Expected Move: $5.62
7-DTE Move: $2.17
Days to Exp: 46 (2026-11-20)

Options Flow · Nov 20 expiry

Call Volume: 4
Put Volume: 1
P/C Volume: 0.25
BULLISH
Call OI: 6
Put OI: 1
P/C OI: 0.167
Total OI: 7

ATM Options Pricing

ATM Call: $2.23
ATM Put: $3.40
Call %: 5.8%
Put %: 8.8%

Chain Summary

Chain Volume: 62
Chain OI: 290
Last Updated: 10/5/2026

BLFS Implied Volatility

30-day IV
46.4%
Oct 5
IV rank
38Medium
Within its 90-session range

Loading implied volatility…

The 30-day IV is the at-the-money implied volatility of options 30 days out, the blue line. The band is its 20-session average, 2 standard deviations either side. Realized volatility is how much BLFS actually moved over the last 20 sessions, from closing prices, on the same yearly scale. Without earnings takes each earnings report out of the 30-day IV, sized from what options paid for past reports, so it shows whether options are expensive or cheap apart from the report. Click a name above the chart to show or hide it.

Spread Scanner

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 37th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
37%
vs own history
GEX tilt
+0.92
OI-weighted, today
Vanna tilt
+0.13
δ-sensitivity to IV
Charm tilt
-0.43
δ-decay vs time
Charm tilt -0.43: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 3 ATM contracts, 0k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Put vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Call vs ATM
IV(call wing) − IV(ATM), in vol points

The same measure on the upside: how the OTM call is priced against the at-the-money strike.

  • Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
  • Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Reading them together

Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d put —
— pts EXTREME
as of Oct 5 · No data
30 DTE / 10d put —
— pts EXTREME
as of Oct 5 · No data

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)6.7LowOct 5
IV Rank (30 DTE)37.7MediumOct 5

Embed BLFS IV rank

BLFS's 30-day IV rank (90 sessions) with its 52-week rank, at-the-money IV and a 90-session trend. Updates after each close. Paste the code into any web page or blog post. Email newsletters drop iframes, so link to the page there.

Theme
Preview
Straddle Price (30 DTE)$5.62Oct 5
Beta Analysis

Risk Metrics

Beta: 1.0663
Alpha: 43.89%
Correlation: 0.3075
R-Squared: 9.5%
Stock Volatility: 44.4%
Market Volatility: 12.8%

Analysis Details

Benchmark: SPY
Data Points: 219
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Notable investors who own BLFS
6 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Soros Fund Management Family office
George Soros, Robert Soros, Jonathan Soros
$26.1M
0.40%
#76 of 245new13F
Millennium Management Hedge fund
Izzy Englander
$17.7M
0.01%
#1199 of 3716new13F
Renaissance Technologies Hedge fund
Jim Simons
$4.9M
0.01%
#1482 of 3151new13F
Citadel Hedge fund
Ken Griffin
$4.5M
0.00%
#2187 of 6285-35.3%13F
Rockefeller Capital Management Family office
Rockefeller family
$2.8M
0.00%
#1261 of 4858-84.0%13F
Point72 Hedge fund
Steve Cohen
$989K
0.00%
#1488 of 1945new13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

BLFS Institutional Ownership (13F)

Filings for 2026-09-30
Diluted shares outstanding: 48,977,843 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

231 filers50,195,920 shares$1.73B value102.49% of float
# Filer Shares Value % of Total % of Float Period
1 BlackRock, Inc. Custodian 6,673,770 $259.28M 14.98% 13.63% 2026-09-30
2 T. Rowe Price Investment Management, Inc. 6,751,135 $190.65M 11.01% 13.78% 2026-06-30
3 Casdin Capital, LLC 4,655,000 $131.46M 7.59% 9.50% 2026-06-30
4 Vanguard Capital Management LLC 1,995,461 $77.52M 4.48% 4.07% 2026-09-30
5 State Street Corp 1,652,823 $64.21M 3.71% 3.37% 2026-09-30
6 First Trust Capital Management L.P. 1,425,085 $55.36M 3.20% 2.91% 2026-09-30
7 Invesco Ltd. Custodian 1,245,629 $48.39M 2.80% 2.54% 2026-09-30
8 Geode Capital Management, LLC Custodian 1,136,220 $44.15M 2.55% 2.32% 2026-09-30
9 Magnetar Financial LLC 1,094,482 $42.52M 2.46% 2.23% 2026-09-30
10 Dimensional Fund Advisors LP Custodian 1,041,425 $40.46M 2.34% 2.13% 2026-09-30
11 Vanguard Portfolio Management LLC 941,310 $36.57M 2.11% 1.92% 2026-09-30
12 Royal Bank of Canada Custodian 789,315 $30.66M 1.77% 1.61% 2026-09-30
13 FRED ALGER MANAGEMENT, LLC 1,077,577 $30.43M 1.76% 2.20% 2026-06-30
14 FMR LLC Custodian 993,106 $28.05M 1.62% 2.03% 2026-06-30
15 WATER ISLAND CAPITAL LLC 716,005 $27.82M 1.61% 1.46% 2026-09-30
16 Bank of America Corp Custodian 950,159 $26.83M 1.55% 1.94% 2026-06-30
17 Stephens Investment Management Group LLC 685,834 $26.64M 1.54% 1.40% 2026-09-30
18 SOROS FUND MANAGEMENT LLC 671,025 $26.07M 1.51% 1.37% 2026-09-30
19 UBS Group AG Custodian 600,978 $23.35M 1.35% 1.23% 2026-09-30
20 Qube Research & Technologies Ltd 548,218 $21.30M 1.23% 1.12% 2026-09-30
21 GAGNON SECURITIES LLC 532,097 $20.67M 1.19% 1.09% 2026-09-30
22 GENEVA CAPITAL MANAGEMENT LLC 507,779 $19.73M 1.14% 1.04% 2026-09-30
23 Millennium Management LLC Custodian 625,658 $17.67M 1.02% 1.28% 2026-06-30
24 Morgan Stanley Custodian 441,217 $17.14M 0.99% 0.90% 2026-09-30
25 CRAMER ROSENTHAL MCGLYNN LLC 575,792 $16.26M 0.94% 1.18% 2026-06-30
4 filers$2.47M notional
# Filer Notional Value % of Total Period
1 Millennium Management LLC Custodian $1.41M 57.09% 2026-06-30
2 Citadel Advisors LLC Custodian $1.01M 40.87% 2026-06-30
3 Simplex Trading, LLC Custodian $46.62K 1.88% 2026-09-30
4 GROUP ONE TRADING LLC Custodian $3.88K 0.16% 2026-09-30
2 filers$1.65M notional
# Filer Notional Value % of Total Period
1 Goldman Sachs Group Inc Custodian $1.06M 64.10% 2026-06-30
2 HARVEST MANAGEMENT LLC $593.04K 35.90% 2026-06-30

BLFS Insider Trading (Form 4)

Latest: 2026-10-08
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-10-08 Rachel Ellingson Director Disp (D) −57,995 — EDGAR
2026-10-08 Amy DuRoss Director Disp (D) −26,857 — EDGAR
2026-10-08 Joydeep Goswami Director Disp (D) −53,156 — EDGAR
2026-10-08 Aby J. Mathew EVP & Chief Scientific Officer Mixed
Grant +86,030 · Tax −70,000 · Disp −404,608
−388,578 $38.61 -$2.70M EDGAR
2026-10-08 Anthony Hunt Director Disp (D) −15,046 — EDGAR
2026-10-08 Troy Wichterman Chief Financial Officer Mixed
Disp −256,000 · Tax −95,933 · Grant +138,504
−213,429 $38.61 -$3.70M EDGAR
2026-10-08 Timothy L. Moore Director Disp (D) −44,943 — EDGAR
2026-10-08 Catherine Coste Director Disp (D) −13,871 — EDGAR
2026-10-08 Sean Werner Chief Technology Officer Mixed
Grant +94,070 · Tax −71,226 · Disp −69,979
−47,135 $38.61 -$2.75M EDGAR
2026-10-08 Roderick De Greef Chief Executive Officer Mixed
Grant +463,130 · Disp −826,454 · Tax −364,872
−728,196 $38.61 -$14.09M EDGAR
2026-10-08 Todd Berard Chief Marketing Officer Mixed
Grant +78,390 · Disp −194,786 · Tax −46,170
−162,566 $38.61 -$1.78M EDGAR
2026-09-22 Aby J. Mathew EVP & Chief Scientific Officer Tax (F) −564 $36.69 -$20.7K EDGAR
2026-09-22 Troy Wichterman Chief Financial Officer Tax (F) −937 $36.69 -$34.4K EDGAR
2026-09-22 Sean Werner Chief Technology Officer Tax (F) −421 $36.69 -$15.4K EDGAR
2026-09-22 Roderick De Greef President and CEO Tax (F) −2,775 $36.69 -$101.8K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

BLFS Insider Holdings

9 insiders · @ $38.61
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Eli Casdin 10%+ Owner 16,306,694 $629.60M $6.59M 4 2025-04-09
2 Casdin Capital, LLC 10%+ Owner 15,264,330 $589.36M $44.26M 9 2025-08-21
3 Casdin Partners Master Fund, L.P. 10%+ Owner 14,664,330 $566.19M -$21.41M 2 2025-10-17
4 Casdin Partners GP, LLC 10%+ Owner 12,328,700 $476.01M -$35.89M 4 2026-05-21
5 Roderick De Greef Chief Executive Officer 439,774 $16.98M -$21.97M 84 2026-10-08
6 Troy Wichterman Chief Financial Officer 183,248 $7.08M -$2.39M 86 2026-10-08
7 Todd Berard Chief Marketing Officer 156,589 $6.05M -$9.27M 109 2026-10-08
8 Karen A. Foster Chief Quality and Operations 111,335 $4.30M -$10.54M 108 2026-03-23
9 Sarah Aebersold Chief Human Resources Officer 92,429 $3.57M -$1.22M 61 2026-03-23
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

BLFS Board & Officers

As of SEC filings through Oct 8, 2026
Changes in the last 10 years (62)
Oct 8, 2026Troy Wichterman reported in an SEC filing no longer being Chief Financial Officer
Oct 8, 2026Todd Berard reported in an SEC filing no longer being Chief Marketing Officer
Oct 8, 2026Timothy L. Moore reported in an SEC filing no longer being a director
Oct 8, 2026Sean Werner reported in an SEC filing no longer being Chief Technology Officer
Oct 8, 2026Roderick De Greef reported in an SEC filing no longer being a director
Oct 8, 2026Roderick De Greef reported in an SEC filing no longer being President and CEO
Oct 8, 2026Rachel Ellingson reported in an SEC filing no longer being a director
Oct 8, 2026Joydeep Goswami reported in an SEC filing no longer being a director
Oct 8, 2026Catherine Coste reported in an SEC filing no longer being a director
Oct 8, 2026Anthony Hunt reported in an SEC filing no longer being a director
Oct 8, 2026Amy DuRoss reported in an SEC filing no longer being a director
Oct 8, 2026Aby J. Mathew reported in an SEC filing no longer being EVP & Chief Scientific Officer
May 21, 2026Eli Casdin reported in an SEC filing no longer being a 10% owner
May 21, 2026Casdin Partners Master Fund, L.P. reported in an SEC filing no longer being a 10% owner
May 21, 2026Casdin Partners GP, LLC reported in an SEC filing no longer being a 10% owner
May 21, 2026Casdin Capital, LLC reported in an SEC filing no longer being a 10% owner
Mar 23, 2026Sarah Aebersold reported in an SEC filing no longer being Chief Human Resources Officer
Jan 8, 2026The company announced the departure of Karen A. Foster as Chief Quality and Operations in an SEC filing
Mar 18, 2025Catherine Coste became a director
Jan 2, 2025Anthony Hunt became a director
Not reported recently (9)
  • Garrie Richardson · Last reported as Chief Revenue Officer in an SEC filing dated Sep 18, 2024
  • Joseph C Schick · Last reported as a director in an SEC filing dated Mar 12, 2024
  • Geraint Phillips · Last reported as SVP, Global Operations in an SEC filing dated Mar 12, 2024
  • Marcus Schulz · Last reported as Chief Revenue Officer in an SEC filing dated Aug 29, 2023
  • Andrew G Hinson · Last reported as a director in an SEC filing dated Aug 18, 2021
  • Raymond W Cohen · Last reported as a director in an SEC filing dated Jul 14, 2021
  • Thomas Girschweiler · Last reported as a director in an SEC filing dated Nov 30, 2020
  • Taurus4757 GmbH · Last reported as a 10% owner in an SEC filing dated Oct 7, 2020
  • James Mathers · Last reported as Chief Revenue Officer in an SEC filing dated Jun 1, 2020
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

BLFS Proposed Insider Sales (Form 144)

Latest: 2026-05-21
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-05-21 Casdin Partners Master Fund, L.P. 10% Shareholder 650,000 $15.60M 2026-05-21 BMO Capital Markets — EDGAR
2026-05-20 Casdin Partners Master Fund, L.P 10% Shareholder 250,000 $6.00M 2026-05-20 BMO Capital Markets — EDGAR
2026-05-19 Casdin Partners Master Fund, L.P. 10% Shareholder 300,000 $6.69M 2026-05-19 BMO Capital Markets — EDGAR
2026-03-23 KAREN FOSTER Officer 2,577 $48.6K 2026-03-23 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-03-09 KAREN FOSTER Officer 500 $9.9K 2026-03-09 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-03-05 KAREN FOSTER Officer 96,923 $2.00M 2026-03-05 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2025-12-15 SARAH AEBERSOLD Officer 713 $17.4K 2025-12-15 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2025-12-04 TROY WICHTERMAN Officer 30,000 $771.5K 2025-12-04 Morgan Stanley Smith Barney LLC … — EDGAR
2025-11-13 RODERICK DE GREEF Officer 31,165 $789.3K 2025-11-13 Morgan Stanley Smith Barney LLC … — EDGAR
2025-11-12 RODERICK DE GREEF Officer 33,418 $865.0K 2025-11-12 Morgan Stanley Smith Barney LLC … — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
8 ETFs hold BLFS
8 shown · $10.11M total exposure
# ETF Provider Weight $ Exposure ETF AUM As Of
1 SCHA Schwab U.S. Small-Cap ETF Nport 0.03% $7.0M — 2026-08-31
2 SCHB Schwab U.S. Broad Market ETF Nport 0.00% $964,636 — 2026-08-31
3 PRFZ Invesco RAFI US 1500 Small-Mid ETF Nport 0.03% $873,869 — 2026-07-31
4 AIMS Acuitas Small Cap Active ETF Nport 0.84% $772,279 — 2026-06-30
5 TILT FlexShares Morningstar US Market Factor Tilt Index Fund Nport 0.01% $175,825 — 2026-07-31
6 MSSM Morgan Stanley Pathway Small-Mid Cap Equity ETF Nport 0.02% $133,526 — 2026-08-31
7 RUSC Russell Investments U.S. Small Cap Equity ETF Nport 0.16% $126,628 — 2026-06-30
8 ISCB iShares Morningstar Small-Cap ETF Nport 0.02% $69,543 — 2026-08-31
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$1.17
TTM Revenue
$102.82M
TTM Net Income
$57.98M
TTM Op. Cash Flow
$16.88M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '262026-06-30$28.47M$45.10M$0.91$6.35M
Q1 '262026-03-31$27.50M$1.19M$0.02$-491.00K
Q4 '252025-12-31$18.79M$11.07M$0.23$4.92M
Q3 '252025-09-30$28.07M$621.00K$0.01$6.10M
Q2 '252025-06-30$23.44M$-15.84M$-0.33$7.37M
Q1 '252025-03-31$22.05M$-448.00K$-0.01$1.73M
Q4 '242024-12-31$15.11M$12.46M$0.27$1.65M
Q3 '242024-09-30$21.39M$-1.70M$-0.04$4.80M
Q2 '242024-06-30$19.71M$-20.72M$-0.45$6.46M
Q1 '242024-03-31$18.43M$-10.22M$-0.22$-4.47M
Q4 '232023-12-31$32.73M$-13.38M$-0.30$2.31M
Q3 '232023-09-30$23.57M$-29.13M$-0.67$-4.58M
Q2 2026 • period ending 2026-06-30 • filed 2026-08-06
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
0.00
P/B
—
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
13.8%
ROA
13.0%
Div Yield
0.00%
FCF Yield
—
Debt/Equity
0.00
Current Ratio
—
Market Cap
$0.00
as of 2026-10-06

BLFS vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
LGND Ligand Pharmaceuticals Inc. $6.0B 130.1 +1.0% +51.3% 46
UFPT UFP Technologies Inc $2.4B 30.7 +8.6% +34.4% 53
BLFS BioLife Solutions Inc. $1.9B 33.0 +25.4% +61.6% —
LMAT LeMaitre Vascular, Inc. $1.7B 26.8 +11.8% −6.9% 47
PDFS PDF Solutions Inc $1.5B 92.8 +22.1% +19.3% 70
TFIN Triumph Financial, Inc. $1.4B 29.2 +12.5% −10.0% 37
PNTG The Pennant Group, Inc. Common Stock $1.3B 34.4 +38.7% +22.3% 43
IRMD iRadimed Corporation $1.1B 43.4 +11.0% −15.0% 32
CVLG Covenant Logistics Group, Inc. $799M 162.5 +12.5% +38.5% 0
Peer median $1.5B 38.9 +12.2% +20.8% 45

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.

Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
4.00M
SI % of Float
8.45%
Days to Cover
4.33
Short Vol Ratio
44.9%
Free Float
47.31M
Float %
96.7%
Short interest 2026-09-30 • Short volume 2026-10-05 • Float 2026-09-08